A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial
Cesar A. Santa‐Maria(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Gary L. Rosner(Johns Hopkins University), Amanda L. Blackford(Johns Hopkins University), John H. Fetting(Johns Hopkins University), Antonio C. Wolff(Johns Hopkins University), Aditya Bardia(UCLA Health), Anne Nguyen(Indiana University School of Medicine), Claire Snyder(Johns Hopkins University), Anna Maria Storniolo(Indiana University Health), Daniel F. Hayes(University of Michigan–Ann Arbor), Katie Quinlan(Johns Hopkins University), Jane Zorzi(Parkland Health & Hospital System), Nora L. Henry(University of Utah), Stacie C. Jeter(Johns Hopkins University), Robert S. Miller(American Society of Clinical Oncology), Shannon A. Slater(Parkland Health & Hospital System), Roisín M. Connolly(Johns Hopkins University)
Cited by 28
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k